High-density lipoprotein antioxidant function is associated with lipid profiles and lipid-lowering therapy

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Clinical Chemistry

Background:

• Dyslipidemia is a key risk factor for coronary artery disease (CAD).
• The role of high-density lipoprotein (HDL) antioxidant function in CAD and its interaction with lipid-lowering therapy requires further investigation.
• Understanding HDL's antioxidant capacity is crucial for managing CAD patients.

Purpose of the Study:

• To analyze the association between HDL antioxidant function, lipid profiles, and lipid-lowering therapy in CAD patients.
• To evaluate HDL antioxidant function as a predictor of CAD.
• To explore the impact of lipid-lowering therapy on HDL antioxidant function.

Main Methods:

• Recruited 1,000 CAD patients and 200 healthy controls.
• Measured HDL lipid peroxide content, normalized by HDL cholesterol (HDL-C) to define HDL antioxidant function (nHDLox).
• Analyzed associations between nHDLox, lipid profiles, CAD severity, lipid-lowering therapy, fasting blood glucose, and inflammatory markers.

Main Results:

• nHDLox levels were elevated in CAD patients and correlated with CAD severity.
• nHDLox demonstrated superior predictive value for CAD compared to triglyceride-glucose index and HDL-C.
• nHDLox positively correlated with total cholesterol, LDL-C, triglycerides, fasting blood glucose, and inflammatory markers.
• Lipid-lowering therapy was associated with improved HDL antioxidant function in CAD patients with controlled LDL-C.

Conclusions:

• HDL antioxidant function is significantly associated with lipid profiles and inflammatory markers in CAD.
• nHDLox can serve as a potential biomarker for CAD prediction and monitoring treatment efficacy.
• Lipid-lowering therapy appears to enhance HDL antioxidant function in CAD patients.